![Figure 1. TEL-FGFR3 transcripts and vector constructs. (A) RT-PCR analysis for detection of TEL-FGFR3 transcripts. Nested RT-PCR was performed using 1 μg RNA from a series of samples of bone marrow (BM) and peripheral blood (PB) obtained from the patient with t(4;12)(p16;p13). The final product was analyzed by electrophoresis on a 1.5% agarose gel in Tris (tris(hydroxymethyl)aminomethane)–borate/EDTA (TBE) buffer, soaked in ethidium bromide, and visualized under UV light. The black arrow indicates the single PCR product (1767 bp). The PCR products from all samples had the same TEL-FGFR3 fusion breakpoint by sequence analysis. The materials (BM or PB) and dates on which the materials were obtained are as follows: BM cells on December 5, 2000 (2 months after the patient was diagnosed with PTCL; lane 1), BM cells on September 12, 2001 (when the patient was diagnosed with AML; lane 2), PB on September 14, 2001 (lane 3), PB on January 8, 2003 (lane 4), and BM cells of a healthy donor as a negative control (lane C). M indicates the molecular size markers. The numbers on the left of the figure indicate the molecular size (in base pair [bp]). (B) Schematic representation of proteins encoded by vector constructs of TEL-FGFR3 and TEL-FGFR3 lacking the HLH domain. (i) Full-length TEL protein of 452 amino acids (aa). The positions of the HLH domain and E26 transformation-specific (ETS) DNA-binding domain are indicated by dark shaded boxes. (ii) Full-length FGFR3 protein of 806 amino acids, which contains 3 extracellular immunoglobulin-like domains, a transmembrane domain, and TK 1 and 2 subdomains interrupted by a kinase insert. (iii) Full-length TEL-FGFR3 fusion protein of 589 amino acids, with a V5 epitope tag (TF-V5). This translocation fused nucleotide (nt) 543 of TEL to nt 1270 of FGFR3 as described previously.16 Closed arrow indicates the t(4;12) fusion breakpoint. Open arrow indicates the CAG trinucleotides insert that was consistently found in the fusion transcripts in all samples from the patient. (iv) ΔHLH-TF-V5, with an in-frame deletion of 76 amino acids (Δ amino acids 39-114 of TF-V5) and which lacks most of the TEL-HLH domain. HLH indicates helix-loop-helix domain; ETS, ETS DNA-binding domain; Ig, immunoglobulin-like domain; TM, transmembrane domain; TK, tyrosine kinase; KI, kinase insert; V5, V5 epitope.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/105/5/10.1182_blood-2003-12-4290/6/zh80050574920001.jpeg?Expires=1724236458&Signature=3V8yKJOKRV50e5axLJDyOxpBBDbRBYcK6NiuVGiKN5ONncL5yqqUWKreobpPV8h3Le26tayEcGHqwhzegs1oY8mx~WAR~0kiWepfB1wAEZBduzrXZBKQd0QZ-~asDOzeSK6X90ZsGxcG~hyEmdlV72va0jRktcyVb3e80J0beIpdDHGvs~k~pdKZUWyf6AoX5DS9zjjd2lsfM~lHCkLWND2bod0PijYyrEwffOzfR7cS4BauZi0P0k5T7ciuK9Bjkdkbpfo26CWKUTjTgHuaPdw2zQRIe7ObaHczf-nXBwfFZnlATVuGgJ57lHus7sczhjh3XAsYdbQmyo3CNLdeiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TEL-FGFR3 transcripts and vector constructs. (A) RT-PCR analysis for detection of TEL-FGFR3 transcripts. Nested RT-PCR was performed using 1 μg RNA from a series of samples of bone marrow (BM) and peripheral blood (PB) obtained from the patient with t(4;12)(p16;p13). The final product was analyzed by electrophoresis on a 1.5% agarose gel in Tris (tris(hydroxymethyl)aminomethane)–borate/EDTA (TBE) buffer, soaked in ethidium bromide, and visualized under UV light. The black arrow indicates the single PCR product (1767 bp). The PCR products from all samples had the same TEL-FGFR3 fusion breakpoint by sequence analysis. The materials (BM or PB) and dates on which the materials were obtained are as follows: BM cells on December 5, 2000 (2 months after the patient was diagnosed with PTCL; lane 1), BM cells on September 12, 2001 (when the patient was diagnosed with AML; lane 2), PB on September 14, 2001 (lane 3), PB on January 8, 2003 (lane 4), and BM cells of a healthy donor as a negative control (lane C). M indicates the molecular size markers. The numbers on the left of the figure indicate the molecular size (in base pair [bp]). (B) Schematic representation of proteins encoded by vector constructs of TEL-FGFR3 and TEL-FGFR3 lacking the HLH domain. (i) Full-length TEL protein of 452 amino acids (aa). The positions of the HLH domain and E26 transformation-specific (ETS) DNA-binding domain are indicated by dark shaded boxes. (ii) Full-length FGFR3 protein of 806 amino acids, which contains 3 extracellular immunoglobulin-like domains, a transmembrane domain, and TK 1 and 2 subdomains interrupted by a kinase insert. (iii) Full-length TEL-FGFR3 fusion protein of 589 amino acids, with a V5 epitope tag (TF-V5). This translocation fused nucleotide (nt) 543 of TEL to nt 1270 of FGFR3 as described previously.16 Closed arrow indicates the t(4;12) fusion breakpoint. Open arrow indicates the CAG trinucleotides insert that was consistently found in the fusion transcripts in all samples from the patient. (iv) ΔHLH-TF-V5, with an in-frame deletion of 76 amino acids (Δ amino acids 39-114 of TF-V5) and which lacks most of the TEL-HLH domain. HLH indicates helix-loop-helix domain; ETS, ETS DNA-binding domain; Ig, immunoglobulin-like domain; TM, transmembrane domain; TK, tyrosine kinase; KI, kinase insert; V5, V5 epitope.
